KALA PHARMCTLS (NASDAQ: KALA) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for KALA PHARMCTLS and Codexis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA PHARMCTLS 0 0 5 0 3.00
Codexis 0 1 3 0 2.75

KALA PHARMCTLS presently has a consensus target price of $36.80, suggesting a potential upside of 72.28%. Codexis has a consensus target price of $6.94, suggesting a potential upside of 27.29%. Given KALA PHARMCTLS’s stronger consensus rating and higher possible upside, research analysts plainly believe KALA PHARMCTLS is more favorable than Codexis.


This table compares KALA PHARMCTLS and Codexis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Codexis -40.70% -83.39% -45.44%

Institutional & Insider Ownership

55.6% of Codexis shares are owned by institutional investors. 9.8% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares KALA PHARMCTLS and Codexis’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Codexis $43.16 million 6.10 -$15.16 million ($0.41) -13.29

KALA PHARMCTLS has higher revenue, but lower earnings than Codexis.


KALA PHARMCTLS beats Codexis on 6 of the 9 factors compared between the two stocks.

KALA PHARMCTLS Company Profile

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient’s eye, often at monthly intervals.

Codexis Company Profile

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Receive News & Stock Ratings for KALA PHARMCTLS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA PHARMCTLS and related stocks with our FREE daily email newsletter.